Aeterna Zentaris Announces Election of Directors at 2015 Shareholders' Meeting

QUÉBEC CITY, May 11, 2015 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announces the results of the vote on directors held at its 2015 Shareholders' meeting on May 8, 2015. Each of the director nominees proposed by management for election was elected as director, without a vote by ballot being conducted. The Company received proxies with regard to voting on the six directors nominated for election as set forth in the table below:

Name of Nominee	Votes For	%	Votes Withheld	%
Marcel Aubut	18,128,464	94.07	1,141,916	5.93
David A. Dodd	18,080,446	93.83	1,189,934	6.17
Carolyn Egbert	18,154,579	94.21	1,115,801	5.79
Juergen Ernst	17,913,295	92.96	1,357,085	7.04
Pierre Lapalme	18,123,537	94.05	1,146,843	5.95
Gérard Limoges	18,149,458	94.18	1,120,922	5.82

All other matters at the shareholders' meeting were also approved by shareholders.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. For more information, visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause Aeterna Zentaris's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of Aeterna Zentaris to efficiently commercialize one or more of its products or product candidates, the ability of Aeterna Zentaris to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process, the ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult Aeterna Zentaris' quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements. Aeterna Zentaris does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.

SOURCE Aeterna Zentaris Inc.

Paul Burroughs, Director of Communications, [email protected], [phone] ext. 406